Guides

Every legitimate self-pay route to a GLP-1 in the US in 2026, priced side by side

By the US Health Digest editorial team · Published August 28, 2026 · Updated August 30, 2026 · Every claim linked to its primary source

The lowest advertised cash price for an FDA-approved GLP-1 in the US today is $149 a month — and it buys a starting oral dose, not a maintenance one. Novo Nordisk's own NovoCare price guide (document US26NC00049, April 2026) puts the Wegovy pill at $149/month for 1.5 mg as a standard offer and at 4.0 mg only as a limited-time one, adding that "4 mg offer only available until August 31, 2026, then $199 per month for 4 mg," and $299/month at 9 mg and 25 mg; Eli Lilly says Foundayo "is available starting at $149 per month at the lowest dose for self-pay patients". For injectables the floor is higher: $299/month for Zepbound's starting dose through LillyDirect, $349/month for standard Wegovy pen doses through NovoCare Pharmacy. Every one of those is a manufacturer's own advertised cash price for one dose tier, tied to conditions, and every one rises as your dose does — which is why the number that matters is the maintenance-dose price, not the starter price.

The routes, side by side

A dozen distinct channels now exist. They are run by different organizations, they buy different things, and their advertised prices are not comparable until you know which kind of price each one is. The table labels every figure: list price (the manufacturer's published price before any discount), manufacturer-direct cash price (what the maker charges a self-payer through its own channel), copay cap (what an insured patient pays after a card is applied), or membership fee (what a service charges for care, separate from the drug).

What actually launched from the federal deal — and what is still an announcement

On November 6, 2025, Lilly announced an agreement with the US government stating that "Starting as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound (tirzepatide), available in a multi-dose pen, and for orforglipron." Read the hedge: as early as, and for orforglipron, if approved. It did not begin in April. The Medicare pathway opened on July 1, 2026 as a time-limited demonstration, running through December 31, 2027. An announced earliest date and a live date are different things, and here they differed by a quarter — which is the general lesson, not a broken promise.

TrumpRx.gov itself did launch. The White House announced it on February 6, 2026 as "a transformative new government platform that gives Americans direct access to dramatically lower prices." In practice it is narrower than that sentence: a price-listing and referral site. Its Zepbound and Foundayo pages hand you to LillyDirect; its Wegovy pill page gives you a coupon to present at a retail pharmacy. The prices it advertises are the manufacturers' own self-pay prices, which is why they match the Lilly and Novo documents above almost exactly. TrumpRx is a useful front door. It is not a separate, cheaper channel, and it is not a pharmacy.

A third piece is announced but not in effect. On February 24, 2026 Novo Nordisk said it will cut the US list price of Wegovy, Ozempic and Rybelsus to $675 per month effective January 1, 2027 — "reductions of approximately 50% and 35% for Wegovy® and Ozempic®, respectively." Check the scope before you plan around it: the company announcement names specific presentations — Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5, 1 and 2 mg, Rybelsus tablets 7 and 14 mg — not every dose. And it is explicit that "these changes in list price do not have an impact on direct-to-patient, self-pay prices." It will help people whose out-of-pocket cost is pegged to list price, such as those in high-deductible or coinsurance plans. It will not lower the $349 at NovoCare Pharmacy.

The oral tier is where the starter price and the real price diverge most

Both oral GLP-1s are priced as ladders, and the rungs are far apart. The Wegovy pill runs $149 at 1.5 mg — and ran $149 at 4.0 mg only until August 31, 2026, after which Novo's own footnote puts 4 mg at $199 — but $299 at 9 mg and 25 mg — and 25 mg is the dose studied in OASIS 4, where the primary treatment-policy result was −13.6% body weight versus −2.2% on placebo over 64 weeks. Foundayo starts at $149 and, on Lilly's own account, rises to as much as $399; the trial behind it, ATTAIN-1, reported −11.2% at the top dose versus −2.1% on placebo at 72 weeks on the treatment-regimen estimand. So the honest reading of a $149 headline is that it prices the months in which the drug is doing the least. Budget for the top of the ladder. We compare the two pills in our guide to oral GLP-1 pills.

What a quoted price does not include

Every figure in the table above is a price for a drug. Five things sit outside it.

• Dose escalation. This is the largest hidden variable, and it is not hidden at all — the manufacturers publish it. Zepbound goes $299 → $399 → $449 as you titrate. The Wegovy pill roughly doubles, $149 → $299 — and from September 1, 2026 its 4 mg rung is $199 rather than $149. Foundayo, on Lilly's own numbers, can more than double. Your month-one bill is not your month-eight bill.
• The refill window. Lilly's Self Pay Journey Program lowers the price of the 7.5, 10, 12.5 and 15 mg vials "only on first fill and when prescriptions are refilled within 45 days of their previous delivery." Miss it and Lilly's December 2025 release puts the 15 mg vial at $1,049; its current KwikPen page puts the 15 mg pen's regular price at $699. Either way, a holiday, a shipping delay or a lapsed prescription can cost more than a month of medication — so ask your program which fallback price applies to your presentation.
• The prescription. Nothing in these programs writes it. TrumpRx requires "a valid prescription"; NovoCare Pharmacy states that "all doses of Wegovy® and Ozempic® require a prescription." Whether that costs a $39 telehealth intake, a $149 membership or a primary-care copay, it is a separate line item.
• Labs and monitoring. Baseline and follow-up bloodwork is ordinary care here, billed by whoever draws it — see what happens in a GLP-1 medical review.
• The cost of stopping. In SURMOUNT-4, participants switched from tirzepatide to placebo regained a substantial share of the weight they had lost while those who continued kept losing. Budgeting a GLP-1 as a three-month purchase misprices it; the evidence is in our page on stopping and regain.

The conceptual version of this argument — why "per month" is the wrong unit at all — is in what GLP-1 treatment really costs without insurance. This page is its operational counterpart.

Copay cards are not a self-pay route

The $25 figures on manufacturer websites are the most misread numbers in this market. They are copay caps, and they require commercial insurance that already covers the drug. Lilly's savings-card terms require that "you are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program." Novo's price guide carries the same exclusion in three words: "Government beneficiaries excluded."

One nuance matters if you are on Medicare or Medicaid and the Bridge program does not fit you. Novo's Wegovy savings-offer terms state that patients "enrolled in government, state, or federally-funded medical or prescription benefit programs are able to pay the self-pay price" — the card is closed to you, the $349 cash channel is not, provided you buy outside your benefit and seek no reimbursement. The same terms clarify that federal employee, ACA exchange and state employee plans are not government programs here, so those enrollees can use the card. If a commercial plan denied you rather than excluded the drug, an appeal is often the higher-value move — see our guide to appealing a GLP-1 denial and our 2026 coverage guide.

The compounded route is closing, not competing

Compounded semaglutide and tirzepatide were, for two years, the cheapest advertised way to obtain these molecules. We do not list a price for them, and that is deliberate. FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list; the comment period was extended on June 26, 2026 to close July 30, 2026, and as of today no further document has published in that docket and no final action has been taken. FDA has separately stated that these products are not FDA-approved and in March 2026 warned 30 telehealth companies over illegal marketing of them. A price attached to a supply a regulator is working to end is not a price you can plan around. The regulatory picture is in our compounded-versus-branded explainer and our coverage of the 503B proposal.

Searching FDA's National Drug Code directory through the openFDA API on August 28, 2026, we found approved generic (ANDA) products for two GLP-1 molecules and neither is the one most people are asking about. Liraglutide has nine ANDA labelers; exenatide has one, Amneal, whose label indicates it only "to improve glycemic control in adults with type 2 diabetes mellitus." The same queries for semaglutide and for tirzepatide returned "No matches found!" There is no legal generic of semaglutide or tirzepatide in the United States, and a generic of an older, weaker, daily molecule is not a substitute for one — that is a clinical judgement, not a pricing one.

Questions to ask before you pay

• What is the price at my maintenance dose, not my starting dose? Ask for the full ladder in writing.
• Is this a list price, a manufacturer-direct cash price, or a copay cap that assumes insurance I do not have?
• Is there a refill window, and what does the medication cost if I miss it by a week?
• Is the prescriber visit included in this number, or billed separately — and is it a one-time fee or recurring?
• Does this price include shipping, and does it include labs?
• Is this an introductory offer with an expiry date? If so, what date, and what is the price after it?
• Is this the FDA-approved product, and which one — brand name, molecule, dose and presentation?
• If I have Medicare, Medicaid, VA or TRICARE coverage: am I excluded from this offer, and can I still buy at the cash price outside my benefit?
• What happens to my price if my dose is reduced, or if I pause treatment for a month?

Prices here move on weeks, not years: three figures above carry expiry dates inside the next four months. Confirm any number with the program's own current page before committing money, and take treatment decisions — including whether a GLP-1 is appropriate at all — with a licensed clinician. This page is information about prices, not medical or financial advice.

Sources

1. Novo Nordisk / NovoCare. Wegovy® price guide, document US26NC00049, April 2026 — self-pay prices for Wegovy pill and pen, the $199 introductory tier through December 31, 2026, the 4 mg pill offer expiring August 31, 2026, and the "$25 (subject to a max savings of $100/mo)" copay offer with "Government beneficiaries excluded." PDF.
2. Novo Nordisk / NovoCare. Ozempic® pill and pen price guide, document US26NC00009, May 2026 — $349/month (0.25–1 mg pen), $499/month (2 mg pen), $199/month for the first two fills through December 31, 2026, pill $149 (1.5 mg) / $199 (4 mg) / $299 (9 mg). PDF.
3. Novo Nordisk / NovoCare. Wegovy® cost and coverage page, document US26NC00039 (2026) — "Wegovy® pill has a list price of $1,349.02/package," the same for the pen and for the HD pen. Link.
4. Novo Nordisk / NovoCare. Explaining the list price of Ozempic®, document US26NC00001 (2026), checked August 28, 2026 — the page carries both $1,027.51 and $997.58 per package, in two blocks of the same page served to different screen widths, undated and with neither marked as superseded; we therefore report both rather than pick one. Link. Explaining the list price of Saxenda®, document US26NC00034 (2026), checked August 28, 2026 — $1,349.02, stated identically in both blocks. Link.
5. Novo Nordisk / NovoCare Pharmacy — free home delivery, no insurance required, prescription required. Link.
6. Novo Nordisk. Wegovy® savings offer terms — government-program exclusion, the FEHB/exchange/state-employee-plan carve-out, and the statement that government-program enrollees "are able to pay the self-pay price." Link.
7. Novo Nordisk. Significant reduction in US list price for Wegovy®, Ozempic® and Rybelsus®, February 24, 2026 — WAC lowered to $675 effective January 1, 2027 for Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5/1/2 mg and Rybelsus tablets 7/14 mg; "reductions of approximately 50% and 35% for Wegovy® and Ozempic®, respectively"; "These changes in list price do not have an impact on direct-to-patient, self-pay prices." Company announcement; wire version.
8. Novo Nordisk. Saxenda® physician site, document US26SX00011, August 2026 — "Novo Nordisk is providing advance notice that we will be discontinuing Saxenda®, with last shipments to wholesalers taking place in late January 2027." Link.
9. Eli Lilly and Company. Lilly lowers the price of Zepbound® single-dose vials, December 1, 2025 — $299 / $399 / $449 by dose for single-dose vials; the footnote scoping the 45-day refill condition to the 7.5, 10, 12.5 and 15 mg vials; and the $849 and $1,049 out-of-window vial prices. Link.
10. Eli Lilly and Company. Foundayo™ (orforglipron) now available in the U.S., April 9, 2026 — "available starting at $149 per month at the lowest dose for self-pay patients," savings card "$25 per month," Medicare Part D "$50 per month, beginning July 1, 2026." Link.
11. Eli Lilly and Company. Lilly and U.S. government agree to expand access to obesity medicines, November 6, 2025 — "Starting as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound (tirzepatide), available in a multi-dose pen, and for orforglipron... provided both receive approval"; Zepbound multi-dose pen "lowest dose at $299, with additional doses up to $449"; orforglipron "lowest dose starting at $149 with additional doses up to $399." These were forward-looking commitments, not prices in effect on the date of the release. Link.
12. Eli Lilly and Company. Mounjaro® savings and resources, document CMAT-31122 08/2026 — "You may pay as little as $25 for up to a 3-month prescription of Mounjaro" and the full government-program exclusion wording. This page does not mention Zepbound. Link. Zepbound® coverage, affordability and savings, document CMAT-26402 07/2026, checked August 28, 2026 — the $299/$399/$449 offer prices, stated to cover "the Zepbound® KwikPen® for single-patient use or 4 vials"; the separate KwikPen regular-price ladder ($299/$399/$499/$699/$699/$699); the Zepbound savings card at "$25 for up to a 3-month prescription"; and the 45-day KwikPen refill condition. Link.
13. The White House. President Trump Launches TrumpRx.gov, February 6, 2026 — launch date and the government's stated before-and-after prices for Ozempic, Wegovy and Zepbound. Link.
14. TrumpRx.gov — live listing prices, and the product pages showing that fulfilment is handled by the manufacturers: home, Zepbound, Foundayo, Wegovy pill. Checked August 28, 2026: the Zepbound and Foundayo pages route to LillyDirect; the Wegovy pill and Ozempic pages issue a retail-pharmacy coupon ("Present the coupon at your pharmacy to claim your TrumpRx savings") with a BIN, PCN, group and member ID. The offer terms are "for self-pay patients only" and impose conditions on — but do not bar — people enrolled in government healthcare programs. TrumpRx's listed prices and expiry wording restate the manufacturers' own documents, including Novo's "4 mg offer only available until August 31, 2026" footnote verbatim.
15. Teva Pharmaceutical Industries. FDA approval and launch of generic Saxenda® (liraglutide injection), August 28, 2025 — described as "the first-ever generic GLP-1 indicated for weight loss." Link.
16. FDA. National Drug Code directory via the openFDA API, searched August 28, 2026 — ANDA liraglutide products from nine labelers (Teva, Biocon, Cipla, Lupin, NorthStar Rx, Hikma, Hybio, Meitheal, Orbicular); ANDA exenatide from one (Amneal, ANDA 206697, marketed since November 22, 2024); "No matches found!" for ANDA semaglutide and for ANDA tirzepatide. Liraglutide query, exenatide query. FDA drug label API, Amneal exenatide injection (ANDA206697): "Exenatide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."
17. FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Link. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s, March 3, 2026. Link.
18. Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B; Extension of Comment Period, document 2026-12937, published June 26, 2026 — comments close July 30, 2026. Link.
19. KFF. What to Know About the Balance Model for GLP-1s in Medicare and Medicaid — Bridge program, $50/month, July 1, 2026 to December 31, 2027. Link.
20. Ro. Weight loss program page — membership pricing and the statement that "the cost of GLP-1 medication is not included in the membership cost." Link.
21. Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025 — primary treatment-policy result −13.6% vs −2.2%, 64 weeks. PubMed 40934115.
22. Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025 — primary treatment-regimen result −11.2% vs −2.1%, 72 weeks. PubMed 40960239.
23. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). PubMed 38078870.